AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 302 min read$TEM

Rogers James William sold $634K of TEM

Rogers James William (Chief Financial Officer) sold 11,529 shares of Tempus AI, Inc. (TEM) at $55.00 ($0.63M total) on 2026-06-25 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Rogers James William
Published Jun 30, 2026, 12:40 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 30, 2026, 1:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$TEM
Neutral
high confidence
Mentioned
$TEM
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TEMNeutralLow
01

Why it matters

The disclosed event is an open-market sale by the CFO for ~$634k, executed under a pre-arranged 10b5-1 plan; this is generally treated as routine unless paired with other negative fundamentals.

02

Market read

Traders may monitor for insider selling trends, but this specific disclosure is unlikely to drive a major repricing on its own.

03

What to watch

The filing does not disclose reasons for the sale beyond the existence of a 10b5-1 plan; without additional context (e.g., other insiders buying, earnings timing), the signal is weak.

Relevance 4/10Novelty 3/10Timing: SEC Form 4 filed late June 29; sale dated June 25.

Background

The article summarizes an SEC Form 4 insider transaction for Tempus AI, Inc. (TEM) involving the CFO.

Company-level read

Ticker impact

$TEMNeutralHigh confidence
Context

Tempus AI CFO Rogers James William sold 11,529 shares in an open-market transaction for about $634,095 under a 10b5-1 plan.

Expected impact

Low near-term impact; any reaction is likely sentiment-driven and short-lived.

Evidence & confidence

The filing is a Form 4 insider sale (not a buy), but it is explicitly tied to a pre-arranged 10b5-1 plan, reducing the likelihood of new, time-sensitive negative information.

Market effects

Sector

Minimal—this is company-specific insider transaction data with no sector-wide catalyst described.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Even with a 10b5-1 plan, repeated insider selling can still reflect management’s view of valuation or liquidity needs; traders may still fade rallies if selling cadence continues.

Key entities

  • public_company
    Tempus AI, Inc.

    Issuer of the Form 4 insider transaction; ticker TEM.

  • insider
    Rogers James William

    Chief Financial Officer who sold 11,529 shares.

  • regulatory_mechanism
    10b5-1 plan

    Pre-arranged trading plan that reduces the informational content of the sale timing.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TEM insider trading history →

Related articles

OCT 26
$TEMMed

What Happens To Tempus AI Stock If Its Cash Burn Continues?

Tempus AI (TEM) expects positive free cash flow by year-end but had a $273M cash burn over the past year. With $816M in cash, the company's reserves could last about three years at current burn rates. Revenue grew 20% and 36% in diagnostics and data businesses, respectively. Management raised 2026 revenue guidance to $1.595B-$1.605B and issued $460M in convertible notes. The company plans to acquire Personalis, potentially using debt to fund the deal.

finance.yahoo.com2 min
OCT 26
$BMYMed

Pathos AI Announces Strategic Collaborations with Bristol Myers Squibb and Tempus AI to Advance AI-Driven Drug Development Beginning with Alzheimer’s Disease and Other Neurological Conditions

Pathos AI has partnered with Bristol Myers Squibb (BMY) and Tempus (TEM) to advance AI-driven drug development for Alzheimer’s and other neurological conditions. Tempus will create a dataset from hundreds of thousands of patients, which Pathos will license for $55 million over five years. BMY leads Pathos's Series E financing and gains access to Pathos's AI platform, Pathos Foundry, for its R&D portfolio, with exclusive rights in neuroscience for three years.

biospace.com3 min
OCT 24
$BMYMed

Tempus Sets $55 Million Ceiling for Pathos Neurology Data Contract

Tempus AI signed a five-year neurology data deal with Pathos AI, potentially worth $55 million. Tempus will deliver up to 500,000 records, with Pathos paying $100 per record. Bristol Myers Squibb gains nonexclusive Foundry access and three-year exclusive rights for neuroscience development. Tempus also has a $137.5 million oncology deal with BMS, totaling $192.5 million if both deals reach full value.

econotimes.com2 min
OCT 23
$TEMMed

Tempus AI Gains 6% as Bristol Myers Squibb Licenses Oncology Data

Tempus AI shares rose 6% after Bristol Myers Squibb agreed to a multi-year deal to license its oncology data through 2031. Tempus's data and AI platform will support BMS's drug discovery and development. Data licensing is Tempus's most profitable segment, with 36% revenue growth in Q2. The financial terms of the deal were not disclosed.

finance.yahoo.com2 min